Unicycive Therapeutics

Company snapshot

Unicycive Therapeutics invent and develop medications that help kidney patients feel their best and enjoy the best possible quality of life.

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 US patent(s) indexed to this assignee profile.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Unicycive Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Unicycive Therapeutics.

1. Jun 8, 2026 Clinical update

   Oxylanthanum Carbonate — Phase 2

2. Aug 26, 2025 Patent grant

   Nicorandil derivatives

3. Aug 5, 2025 Patent grant

   Nicorandil derivatives

4. Jul 16, 2024 Patent grant

   Nicorandil derivatives

5. Aug 9, 2022 Patent grant

   Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use

View all clinical trial activity →

• What is Unicycive Therapeutics?

  Unicycive Therapeutics is a pharma organization headquartered in Los Altos, USA. It trades on NYSE under ticker UNCY. Primary therapeutic focus areas include Chronic Kidney Disease Requiring Chronic Dialysis. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 4 pa

• Is Unicycive Therapeutics publicly traded?

  Yes. Unicycive Therapeutics is listed with ticker UNCY on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Unicycive Therapeutics develop or market?

  We link 3 drug profile(s) where Unicycive Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/unicycive-therapeutics#company-drugs.

• What are the latest developments for Unicycive Therapeutics?

  In the last 12 months our linked public records show 1 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Unicycive Therapeutics focus on?

  Unicycive Therapeutics focuses on Chronic Kidney Disease Requiring Chronic Dialysis based on our analysis of their pipeline programs and drug development activities.